Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves' disease-A multicenter study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1648-1655

  Diana, T ^a   Brown, R S ^b   Bossowski, A ^c   Segni, Maria ^d   Niedziela, M ^e   Konig J ^a   Bossowska, A ^f   Ziora, K ^g   Hale, A ^b   Smith, J ^b   Pitz, S ^a   Kanitz, M ^a   Kahaly, G J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f Department of Cardiology Internal Affair and Administration Ministry Hospital   (Poland)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN; THYROID STIMULATING HORMONE BINDING INHIBITORY IMMUNOGLOBULIN; THYROID STIMULATING IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY DETECTION; ARTICLE; AUTOMATION; BIOASSAY; BLOOD LEVEL; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENDOCRINE OPHTHALMOPATHY; FEMALE; FUNCTIONAL ASSESSMENT; GRAVES DISEASE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; THYROID FUNCTION;

ADOLESCENT; AUTOIMMUNE DISEASES; CHILD; FEMALE; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; MALE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROID HORMONES; YOUNG ADULT;

EID: 84899927845     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4026     Document Type: Article

References (39)

1. Bauer AJ. Approach to the pediatric patient with Graves'disease when is definitive therapy warranted J Clin Endocrinol Metab. 201196 580-588.
2. Léger J, Carel JC. Hyperthyroidism in childhood: causes, when and how to treat. J Clin Res Pediatr Endocrinol. 2013;5(suppl 1):50-56.
3. Krassas GE, Segni M, Wiersinga WM. Childhood Graves'ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol. 2005;153:515-521.
4. Krassas GE, Gogakos A. Thyroid-associated ophthalmopathy in juvenile Graves'disease-clinical, en docrine and therapeutic aspects. J Pediatr Endocrinol Metab. 2006;19:1193-1206.
5. Rivkees SA, Stephenson K, Dinauer C. Adverse events associated with methimazole therapy of Graves'disease in childr en. Int J Pediatr Endocrinol. 2010;2010:176970.
6. Segni M, Leonardi E, Mazzoncini B, Pucarelli I, Pasquino AM. Special features of Graves'disease in early childhood. Thyroid. 1999; 9:871-877.
7. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical feature s at diagnosis and responses to medical therapy. Thyroid. 1997;7:755-760.
8. Goldstein SM, Katowitz WR, Moshang T, Katowitz JA. Pediatric thyroid-associated orbitopathy: The Children's Hospital o f Philadelphia experience and literature review. Thyroid. 2008;18:997-999.
9. Holt H, Hunter DG, Smith J, Dagi LR. Pediatric Graves'ophthalmopathy: The pre-and postpubertal experience. J AAPOS. 2008; 12:357-360.
10. Nebesio TD, Eugster EA. Images in clinical medicine. Delayed Graves'ophthalmopathy. N Engl J Med. 2010;362:e60.
11. Brent GA. Clinical practice. Graves 'disease. N Engl J Med. 2008; 358:2594-2605.
12. Foley TP Jr. Mediators of thyroid diseases in children. J Pediatr. 1998;132:569-570.
13. Gassner D, Stock W, Golla R, Roth HJ. First automated assay for thyrotropin receptor autoantibodies. Clin Chem Lab Med. 2009; 47:1091-1095.
14. SchottM,Hermsen D, Broecker-PreussM,et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves'disease (GD): an international multicentre trial. Clin Endocrinol (Oxf). 2009;71:566-573.
15. Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves'disease treated using antithyroid medication. Thyroid. 2007;17:1103-1107.
16. Glaser NS, StyneDM,Organization of Pediatric Endocrinologists of Northern California Collaborative Graves'Disease Study Group. Predicting the likelihood of remission in children with Graves'disease: a prospective, multicenter study. Pediatrics. 2008;121:e481-488.
17. Foley TP Jr., White C, New A. Juvenile Graves'disease: usefulness and limitations of thyrotropin receptor antibody determinations. J Pediatr. 1987;110:378-386.
18. Botero D, Brown RS. Bioassay of thyrotropin receptor antibodies with Chinese hamster ovary cells transfected with recombinant human thyrotropin receptor: clinical utility in children and adolescents with G raves'disease. J Pediatr. 1998;132:612-618.
19. Rahhal SN, Eugster EA. Thyroid stimulating immunoglobulin is often negative in children with Graves'disease. J Pediatr Endocrinol Metab. 2008;21:1085-1088.
20. European Group on Graves 'Orbitopathy (EUGOGO), Wiersinga WM, Perros P, Kahaly GJ, et al. Clinical assessment of patients with Graves'orbitopathy: The European Group on Graves'Orbitopathy recommendation s to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155:387-389.
21. Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European Group on Graves'Orbitopathy (EUGOGO) on management of Graves'orbitopathy. Thyroid. 2008;18:333-346.
22. Dickinson AJ Clinical Manifestations. In Wiersinga WM, Kahaly GJ, eds. Graves'Orbitopathy: A Multidisciplinary Approach-Questions and Answers. 2nd revised ed. Basel, Switzerland: Karger 2010 1-25.
23. Lytton SD, Li Y, Olivo PD, Kohn LD, Kahaly GJ. Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol. 2010;162:438-446.
24. Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves'orbitopathy. J Clin Endocrinol Metab. 2010;95:2123-2131.
25. Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ. Clinical relevance of thyroid-stimulating immunoglobulins in Graves'ophthalmopathy. Ophthalmol ogy. 2011;118:2279-2285.
26. Kubo T, Shimizu J, Furujo M, et al. An infant case of Graves'disease with ophthalmopathy. Endocr J. 2005;52:647-650.
27. Shib ayama K, Ohyama Y, Yokota Y, Ohtsu S, Takubo N, Matsuura N. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves'disease. Endocr J. 2005;52:505-510.
28. Léger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C, French Childhood Graves'Disease Study Group. Positive impact of longterm antithyroid drug treatment on the outcome of children with Graves 'disease: national long-term cohort study. J Clin Endocrinol Metab. 2012;97:110-119.
29. Kaguelidou F, Alberti C, Castanet M, et al. Predictors of autoimmune hyperthyroidism relapse in children after d iscontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008;93: 3817-3826.
30. Barbesino G, Tomer Y. Clinical review: clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98:2247-2255.
31. Leschik JJ, Diana T, Olivo PD, et al. Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol. 2013; 139:192-200.
32. Kamijo K, Murayama H, Uzu T, Togashi K, Kahaly GJ. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differen tiation of Graves'disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid. 2010;20:851-856.
33. Kamijo K, Murayama H, Uzu T, T ogashi K, Olivo PD, Kahaly GJ. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves'disease. Thyroid. 2011; 21:1295-1299.
34. Spaulding SW. The diluted TSHR antibody titer in untreated Graves'disease may predict who will respond to six month's treatment with methimazole, and Mc4-expressing CHO cells can detect both blocking and stimulating TSHR antibodies. Clin Thyroidol. 2013;25:158-161.
35. Li Y, Kim J, Diana T, Klasen R, Olivo PD, Kahaly GJ. A novel bioassay for anti-thyrotrophin receptor autoantibodies d etects both thyroid-blocking and stimulating activity. ClinExpImmunol. 2013; 173:390-397.
36. Giuliani C, Cerrone D, Harii N, et al. A TSHr-LH/CGr chimera that measures functional TSAb in Graves'disease. J Clin Endocrinol Metab. 2012;97:E1106-E1115.
37. Giuliani C, Cerrone D, Harii N, et al. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves'patients undergoing antithyroid drug (ATD) treatment. J Clin Endocrinol Metab. 2012;97: E1080-E1087.
38. Lee JI, Jang HW, Kim SK, et al. Diagnostic value of a chimeric TSH receptor (Mc4)-based bioassay for Graves'disease. Korean J Intern Med. 2011;26:179-186.
39. Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clin ical Endocrinologists. Thyroid. 2011;21:593-646.